ClinicalTrials.gg
Active, not recruitingNCT06427395Updated May 12, 2026

Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis

A Phase 3 interventional study of Saroglitazar Magnesium 1 mg in Primary Biliary Cholangitis, sponsored by Zydus Therapeutics Inc.. Active, not recruiting at 28 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Zydus Therapeutics Inc. (part of Zydus Lifesciences Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
102
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies in Liver Cirrhosis, Biliary with a site in United States — 11 open to participants now, 18 under way, 8 of them phase 3. Liver Cirrhosis, Biliary · United States.

Enrollment
18th of 65
102 · median 46
Started
2024
with 6 others
Phase 3
16 of 83
4 open now
Primary completion
2027-04
later than 4 of 17 live
Registered
72nd of 83
by date
Lead sponsor
6 of 83
Zydus Therapeutics Inc.

Among the 83 studies in Liver Cirrhosis, Biliary with a site in United States, this one is the 18th largest by enrollment of the 65 interventional ones that give a count, is one of 7 that started in 2024, is one of 16 in phase 3, reaches primary completion later than 4 of the 17 other live ones, and was the 72nd registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

11 of the 83 studies in Liver Cirrhosis, Biliary with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Liver Cirrhosis, Biliary with a site in United States, or all of them as a file.
02

Study summary

Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis

Read the detailed description

A Multicenter, Open-Label, Extension Clinical trial to evaluate Safety and Efficacy of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis (PBC)

03

Conditions studied

  • Primary Biliary Cholangitis

Keywords

  • Saroglitazar Magnesium
  • Primary Biliary Cholangitis
  • PBC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must provide written and agree to comply with the trial protocol
  2. Participated and completed SARO.21.001, the double-blind treatment phase study

Exclusion criteria

Exclusion Criteria:

  1. Consumption of 2 standard drinks per day if male and 1 standard drink per day if female for 3 consecutive months (12 consecutive weeks) throughout double-blind phase till screening.
  2. Participants with MELD 3.0 score of 15 or greater
  3. History or presence of other concomitant liver diseases at screening:

    1. Chronic or C virus (HBV, ) infection
    2. Primary sclerosing cholangitis (PSC)
    3. Alcoholic liver disease
    4. hepatitis (AIH)-PBC overlap syndrome
    5. Hemochromatosis
    6. Non-alcoholic steatohepatitis (NASH) on historical
  4. Cirrhosis with complications, including history or presence of: spontaneous bacterial peritonitis, hepatocellular carcinoma, uncontrolled ascites, encephalopathy, history of variceal bleeding or history of hepatorenal syndrome at screening.
  5. Use of Thiazolidinediones or Fibrates (within 12 weeks prior to screening)
  6. Use of other PPAR agonists (i.e., Elafibranor, Seladelpar), Obeticholic acid (OCA), methotrexate, budesonide and other systemic (Prednisone dose more than 10 mg); potentially hepatotoxic drugs (including α-methyl-dopa, sodium valproic acid, isoniazid, or nitrofurantoin) (within 12 weeks prior to screening)
  7. History of bowel surgery (gastrointestinal [bariatric] surgery in the preceding 1 year or undergoing evaluation for gastrointestinal surgery (bariatric surgery for obesity, extensive small-bowel resection) or orthotopic liver transplant (OLT) or listed for OLT
  8. Unstable cardiovascular disease, including:

    1. Unstable angina, (i.e., new or worsening symptoms of coronary heart disease in the 12 weeks before screening and throughout the screening period), acute coronary syndrome in the 24 weeks before screening and throughout the screening period, acute myocardial infarction in the 12 weeks before screening and throughout the screening period or heart failure of class (III - IV) or worsening congestive heart failure, or coronary artery intervention, in the 24 weeks before screening and throughout the screening period
    2. History/current unstable cardiac dysrhythmias
    3. Uncontrolled hypertension at screening
    4. Stroke or in the 24 weeks before screening
  9. History of intracranial hemorrhage, arteriovenous malformation, bleeding disorder, and coagulation disorders
  10. An uncontrolled thyroid disorder

    1. Uncontrolled hyperthyroidism: defined as any history of hyperthyroidism that has either not been treated with either radioactive iodine and/or surgery or that has been treated with radioactive iodine and/or surgery, but has required ongoing continuous or intermittent use of thyroid hormone synthesis inhibitors (i.e., methimazole or propylthiouracil) in the 24 weeks before screening
    2. Uncontrolled hypothyroidism: defined as initiation of thyroid hormone replacement therapy or dose adjustment of replacement therapy in the 12 weeks before screening
  11. History of myopathies or evidence of active muscle disease demonstrated by CPK ≥ 5 × at screening
  12. Any of the following laboratory values:

    1. Total > 3 x ULN
    2. \< 50 × 103/mL
    3. Albumin \< 2.8 g/dL
    4. \< 45 mL/min/1.73 m2
    5. or AST > 250 U/L
    6. ALP > 10 × ULN
  13. Participation in another interventional clinical study and receipt of any other medication or medical device within 30 days or within 5 half-lives, whatever is longer, prior to screening
  14. History of in the past 5 years and/or active neoplasm which may diminish (except resolved superficial non-melanoma skin cancer, carcinomas in situ or other stable, relatively benign conditions if appropriately treated prior to screening)
  15. Known allergy, sensitivity or intolerance to the study medication or formulation ingredients
  16. Pregnancy-related exclusions, including:

    1. Pregnant/lactating female (including positive pregnancy test at screening)
    2. Participants agree to avoid pregnancy either by true abstinence or the use of an acceptable effective measures for the duration of the study and for at least 1 month after the end of the study medication. Refer Appendix 9 Contraceptive Guidance.
  17. History or other evidence of severe illness or any other conditions that would make the participant, in the opinion of the investigator, unsuitable for the study (such as poorly controlled psychiatric disease, , coronary artery disease or active gastrointestinal conditions that might interfere with drug absorption)
  18. Cirrhosis with -Turcotte (CPT) class B or C having score of 7 or above at screening (Refer Appendix 11
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Saroglitazar Magnesium 1 mg

    Saroglitazar Magnesium 1 mg tablet orally administered once daily in the morning before breakfast without food, for the duration of treatment (24 months).

    Drug: Saroglitazar Magnesium 1 mg

Interventions

  • Saroglitazar Magnesium 1 mg will be assigned to all participants enrolled in the open label extension program

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: From baseline to 24 Months/EOT

Secondary outcomes

  1. Proportion of participants achieving biochemical response based on the composite endpoints of ALP and total bilirubin

    ALP \< 1.67 x ULN, ≥ 15% decrease in ALP, and total bilirubin ≤ ULN or direct bilirubin ≤ ULN relative to baseline in participants with known Gilbert's syndrome

    Time frame: From baseline to Months 12 and 24/EOT

  2. Proportion of participants with biochemical response based on the composite endpoints of ALP and total bilirubin

    complete normalization of ALP. Change and percent change from baseline in ALP

    Time frame: From baseline to Months 12 and 24/EOT

  3. Time to occurrence of the clinical outcome events in study participants with PBC

    Defined as new onset or recurrence of any of the following: * Hospitalization for new onset or recurrence of variceal bleed * Hepatic encephalopathy (as defined by a West Haven score ≥2) * New onset ascites requiring treatment * Refractory ascites (requiring large volume paracentesis) * Spontaneous bacterial peritonitis (confirmed by culture from diagnostic paracentesis)

    Time frame: From baseline to 24 Months/EOT

  4. Time to occurrence of the clinical outcome events based on Model for End Stage Liver Disease 3.0 score

    Time from enrolment to the first occurrence of Model for End Stage Liver Disease 3.0 score ≥ 15 and 25% increase from baseline as measured on 2 consecutive occasions performed at least two weeks apart with no competing etiologies identified

    Time frame: From baseline to 24 Months/EOT

  5. Time to first occurrence of Liver transplant or placement on a liver transplant list

    Time frame: From baseline to 24 Months/EOT

  6. Time to the occurrence of Death

    Death (liver and non-liver related)

    Time frame: From baseline to 24 Months/EOT

  7. Effect on liver enzyme parameters

    Change from baseline in ALT

    Time frame: From baseline to Months 12 and 24/EOT

  8. Effect on liver enzyme parameters

    Change from baseline in AST

    Time frame: From baseline to Months 12 and 24/EOT

  9. Effect on liver enzyme parameters

    Change from baseline in GGT

    Time frame: From baseline to Months 12 and 24/EOT

  10. Effect on liver enzyme parameters

    Change from baseline in total bilirubin

    Time frame: From baseline to Months 12 and 24/EOT

  11. Effect on lipid parameters

    Change from baseline in TG

    Time frame: From baseline to Months 12 and 24/EOT

  12. Effect on lipid parameters

    Change from baseline in LDL-C

    Time frame: From baseline to Months 12 and 24/EOT

  13. Effect on lipid parameters

    Change from baseline in HDL-C

    Time frame: From baseline to Months 12 and 24/EOT

  14. Effect on lipid parameters

    Change from baseline in VLDL-C

    Time frame: From baseline to Months 12 and 24/EOT

  15. Effect on lipid parameters

    Change from baseline in total cholesterol

    Time frame: From baseline to Months 12 and 24/EOT

  16. Effect on lipid parameters

    Change from baseline in non-HDL-C

    Time frame: From baseline to Months 12 and 24/EOT

  17. Effect on liver enzyme parameters

    Change from baseline in serum bile acids

    Time frame: From baseline to Months 12 and 24/EOT

  18. Effect on disease-related symptoms

    Change from baseline in quality of life (Primary Biliary Cholangitis- 40) questionnaire domains Scale as Never, Rarely, Sometimes, Most of the time, and Always

    Time frame: From baseline to Months 12 and 24/EOT

  19. Effect on disease-related symptoms

    Change from baseline in 5-D itch scale Score ranging from 5 to 25, where higher score represents worst itching

    Time frame: From baseline to Months 12 and 24/EOT

  20. Effect on disease-related symptoms

    Change from baseline in Worst Itch NRS (numerical rating scale) scores 0-10, where 0 is no itch and 10 is worst itch imaginable

    Time frame: From baseline to Months 12 and 24/EOT

  21. Effect on liver stiffness measurement (LSM) assessed by Liver elastography/FibroScan

    Change from baseline in LSM assessed by Liver elastography/FibroScan

    Time frame: From baseline to Months 12 and 24/EOT

07

Study locations

28 sites
  • Zydus US013
    Los Angeles, California 90048, United States
  • Zydus US011
    Pasadena, California 91105, United States
  • Zydus US043
    Sacramento, California 95817, United States
  • Zydus US022
    Aurora, Colorado 80045, United States
  • Zydus US037
    New Haven, Connecticut 06520, United States
  • Zydus US027
    Jacksonville, Florida 32224, United States
  • Zydus US006
    Lakewood Rch, Florida 34211, United States
  • Zydus US005
    Miami, Florida 33136, United States
  • Zydus US020
    Marietta, Georgia 30060, United States
  • Zydus US001
    Indianapolis, Indiana 46202, United States
  • Zydus US035
    Rochester, New York 14642, United States
  • Zydus US002
    Charlotte, North Carolina 28204, United States
  • Zydus US042
    Houston, Texas 77030, United States
  • Zydus US031
    Murray, Utah 84107, United States
  • Zydus US016
    Charlottesville, Virginia 22908, United States
  • Zydus US039
    Richmond, Virginia 23298, United States
  • Zydus US033
    Seattle, Washington 98105, United States
  • Zydus AR001
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1118AAT, Argentina
  • Zydus AR007
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1199ABB, Argentina
  • Zydus AR006
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1221ADC, Argentina
  • Zydus AR005
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1425BGC, Argentina
  • Zydus AR003
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1430CKE, Argentina
  • Zydus AR004
    Pilar, Buenos Aires B1629ODT, Argentina
  • Zydus TR016
    Altındağ, 06230, Turkey (Türkiye)
  • Zydus TR004
    Ankara, 06800, Turkey (Türkiye)
  • Zydus TR005
    Bursa, 16059, Turkey (Türkiye)
  • Zydus TR017
    Cebeli, 06620, Turkey (Türkiye)
  • Zydus TR015
    Melikgazi, 38039, Turkey (Türkiye)
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Apr 2027, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2024
First posted
May 23, 2024
StartActual
Jul 16, 2024
Primary completionEst.
Apr 18, 2027
CompletionEst.
Jul 18, 2027
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06427395
Responsible party
Sponsor
First posted
May 23, 2024
Start date
Jul 16, 2024
Primary completion
Apr 18, 2027 (estimated)
Completion
Jul 18, 2027 (estimated)
Last update
May 12, 2026

Study contacts

Deven Parmar
study director · Zydus Therapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Saroglitazar

Start the discussion